NMTR - NMTR STOCK NEWS

9 Meters Biopharma (NASDAQ:NMTR) announced that CEO John Temperato will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 4, 2021, from 12:30 to 12:55 p.m. ET. Investors can participate via a webcast and arrange one-on-one meetings with management. The conference will feature over 400 healthcare companies and 3,000 executives, exploring investment opportunities and trends in healthcare. Following the session, a replay will be available for 30 days.

9 Meters Biopharma (NASDAQ:NMTR) announced a publication in the Journal of Clinical Investigation detailing the use of larazotide under an FDA-approved Expanded Access Program in treating a 17-month infant with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19. Results showed a significant reduction in inflammatory markers, including a 98% drop in SARS-CoV-2 nucleocapsid protein. This supports larazotide's role in restoring gut mucosal integrity and mitigating MIS-C symptoms. The publication strengthens the case for larazotide's clinical efficacy.

9 Meters Biopharma (NASDAQ:NMTR) has announced that CEO John Temperato will present a corporate update at Oppenheimer's Rare & Orphan Disease Summit on May 21, 2021, from 3:45 - 4:25 p.m. ET. Investors can participate via a webcast and schedule one-on-one meetings with management. The company focuses on developing treatments for rare gastroenterological diseases, notably advancing vurolenatide and larazotide. A replay of the event will be available for 90 days after the presentation.

9 Meters Biopharma, Inc. (NASDAQ:NMTR) will provide a corporate update at Oppenheimer's Rare & Orphan Disease Summit, scheduled for May 21, 2021. CEO John Temperato's presentation will occur from 3:45 - 4:25 p.m. (ET), with opportunities for one-on-one meetings. The event aims to discuss the company’s advancements in gastroenterology, particularly focusing on the Phase 2 trial of vurolenatide for short bowel syndrome and larazotide in Phase 3 for celiac disease. A webcast will be available at https://wsw.com/webcast/oppenheimer12/nmtr/2813759.

9 Meters Biopharma (NASDAQ:NMTR) announced that the USAN Council designated its drug candidate NM-002 for short bowel syndrome as vurolenatide. The drug is a long-acting injectable GLP-1 receptor agonist aimed at improving quality of life for SBS patients by mitigating chronic diarrhea. The company plans to initiate a large Phase 2 trial focusing on total stool output as the primary efficacy endpoint. This trial follows positive results from a previous study and demonstrates the company’s commitment to addressing unmet medical needs in gastroenterology.

9 Meters Biopharma (NASDAQ:NMTR) reported a net loss of $5.4 million for Q1 2021, compared to $3.6 million in Q1 2020, with cash and equivalents totaling $38.5 million. The company closed a $31.5 million equity offering, ensuring a sufficient cash runway into 2023. Upcoming milestones include the initiation of a Phase 2 trial for NM-002 in short bowel syndrome by Q2 2021 and a collaboration with the Celiac Disease Foundation to support a Phase 3 trial for larazotide. Topline Phase 2 results are anticipated by Q4 2021.

9 Meters Biopharma (NASDAQ: NMTR) announced participation in the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021. Management will engage in virtual one-on-one meetings with investors, emphasizing their focus on rare gastroenterology needs. The company is advancing drug candidates, including NM-002 for short bowel syndrome and larazotide for non-responsive celiac disease, into clinical trials. For virtual meeting scheduling, contact your Truist Securities representative or visit the conference website.

9 Meters Biopharma (NASDAQ:NMTR) announced a collaboration with the Duke Clinical Research Institute to advance its clinical candidate NM-002, a GLP-1 agonist for short bowel syndrome (SBS), currently in Phase 2 trials. SBS is a serious condition impacting nutrient absorption. NM-002 has shown promising topline data, demonstrating improved stool output and bowel frequency. The Phase 2 trial aims to establish safety and efficacy with results expected in Q4 2021, while a Phase 3 trial is anticipated to follow.

9 Meters Biopharma (NASDAQ:NMTR) announced a collaboration with the Celiac Disease Foundation to enhance clinical trial enrollment for its Phase 3 study, CeDLara, investigating the drug larazotide for celiac disease patients. The trial aims to demonstrate larazotide's safety and efficacy for adults who experience symptoms despite a gluten-free diet. Interim results are expected in 2022. Current therapies are inadequate as they only involve strict adherence to a gluten-free diet, highlighting the need for effective alternatives.